Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer [Phase 1]

View source ↗

Summary

This update announces a Phase 1 study to evaluate the safety and tolerability of TOS-358 in women with HR+/HER2-negative breast cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TOS-358

Snippet

Sponsor: Totus Medicines | Conditions: HR+/HER2-negative Breast Cancer | Phase 1 | Status: RECRUITING